ESMO 2024
PULMÓN
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Updated efficacy and safety from the phase II PHAROS
study of encorafenib plus
binimetinib in patients with BRAF V600E-mutant
metastatic NSCLC (mNSCLC)
LBA56
Mechanisms of acquired resistance to first-line
amivantamab plus lazertinib versus osimertinib in patients
with EGFR-mutant advanced non-small cell lung cancer:
An early analysis from the phase III MARIPOSA study
LBA55
Osimertinib (osi) after definitive chemoradiotherapy (CRT)
in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS
and distant progression from the Phase 3 LAURA study
1241MO
Precision immuno-oncology for advanced non-small cell
lung cancer (NSCLC) patients with PD-(L)1 inhibitors
resistance (PIONeeR): A phase Ib/IIa clinical trial targeting
identified resistance pathways
LBA8
Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with
KRASG12C-mutated advanced NSCLC and baseline brain
metastases (BM): Results from KRYSTAL-12
LBA57
ABBV-400 a c-Met protein-targeting antibody-drug
conjugate (ADC), in patients (Pts) with advanced EGFR
wildtype (WT) non-squamous (NSQ) non-small cell lung
cancer (NSCLC): Results from a phase I study
1257MO
LOCALMENTE AVANZADO O METASTÁSICO
Regístrate aquí para recibir más contenidos
Registrarse